Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20178574 | 0.85 | ERAP2 (0.46) | — | |
| SCHEMBL10587906 | 0.82 | PTPN11 (0.47) | RARBTP53TSHRPLA2G4B | |
| SCHEMBL20178550 | 0.81 | TSHR (0.52) | TP53TSHRPLA2G4B | |
| SCHEMBL24653299 | 0.79 | GCGR (0.38) | — | |
| SCHEMBL22792006 | 0.79 | GCGR (0.38) | — | |
| SCHEMBL12491998 | 0.79 | ACE2 (0.60) | RARBTSHR | |
| SCHEMBL7691383 | 0.77 | LMNA (0.51) | RARBTP53TSHRPLA2G4B | |
| SCHEMBL7691386 | 0.77 | LMNA (0.51) | RARBTP53TSHRPLA2G4B | |
| SCHEMBL19374835 | 0.77 | LMNA (0.41) | RARBTSHR | |
| SCHEMBL9226690 | 0.76 | RARB (0.51) | RARBTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | RARB 877/4885TP53 4394/4885TSHR 320/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | RARB 877/4885TP53 4394/4885TSHR 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.